BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in ...

Retrieved on: 2023-01-08 19:49:13

Tags for this article:

Branches of biology

Life Sciences

BioMarin Pharmaceutical

u.s. food and drug administration

Click the tags to see associated articles and topics

BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in .... View article details on HISWAI: https://www.prnewswire.com/news-releases/biomarin-announces-stable-and-durable-annualized-bleed-control-for-roctavian-in-largest-phase-3-gene-therapy-study-in-adults-with-severe-hemophilia-a-134-participant-study-met-all-primary-and-secondary-efficacy-endpoints-at-3-ye-301716007.html

Excerpt

PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic ...

Article found on: www.prnewswire.com

View Original Article